Eisai and Sysmex team up to develop Alzheimer in-vitro diagnostics

The test will be based on a patient’s serum but the targe of the test has not been announced. It will either be based on an immune complex transfer methods based on Sysmex’ HISCL analyzers, or a super-resolution molecular imaging of a fluorescence-labeled target protein.

Eisai news release February 16, 2016

Most popular posts:

This website stores cookies on your computer. These cookies are used to provide a more personalized experience and to track your whereabouts around our website in compliance with the European General Data Protection Regulation. If you decide to to opt-out of any future tracking, a cookie will be setup in your browser to remember this choice for one year.

Accept or Deny